RESUMO
The performance of quantum key distribution (QKD) is severely limited by multiphoton pulses emitted by laser sources due to the photon-number splitting attack. Coherent-one-way (COW) QKD has been introduced as a promising solution to overcome this limitation, and thus extend the achievable distance of practical QKD. Indeed, thanks to its experimental simplicity, the COW protocol is already used in commercial applications. Here, we derive simple upper security bounds on its secret key rate, which demonstrate that it scales at most quadratically with the system's transmittance, thus solving a long-standing problem. That is, in contrast to what has been claimed, this approach is inappropriate for long-distance QKD transmission. Remarkably, our findings imply that all implementations of the COW protocol performed so far are insecure.
RESUMO
Since hydrogel therapies have been introduced into clinic treatment procedures, the biomedical industry has to face the technology transfer and the scale-up of the processes. This will be key in the roadmap of the new technology implementation. Transfer technology and scale-up are already known for some applications but other applications, such as 3D printing, are still challenging. Decellularized tissues offer a lot of advantages when compared to other natural gels, for example they display enhanced biological properties, due to their ability to preserve natural molecules. For this reason, even though their use as a source for bioinks represents a challenge for the scale-up process, it is very important to consider the advantages that originate with overcoming this challenge. Therefore, many aspects that influence the scaling of the industrial process should be considered, like the addition of drugs or cells to the hydrogel, also, the gelling process is important to determine the chemical and physical parameters that must be controlled in order to guarantee a successful process. Legal aspects are also crucial when carrying out the scale-up of the process since they determine the industrial implementation success from the regulatory point of view. In this context, the new law Regulation (EU) 2017/745 on biomedical devices will be considered. This review summarizes the different aspects, including the legal ones, that should be considered when scaling up hydrogels of natural origin, in order to balance these different aspects and to optimize the costs in terms of raw materials and engine.